ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics

▤ Summary

ChemDiv says its proprietary CNS drug discovery platform has helped advance neurodegenerative programs for Polku Therapeutics and Brenig Therapeutics. The platform supported the design and optimization of brain-penetrant small molecules aimed at difficult CNS targets. Brenig’s programs have moved into clinical development, while Polku reported positive preclinical results for its lead compound POLK-38 in a mouse model of Alzheimer’s-related disease. The update highlights ChemDiv’s role in enabling partners to move from discovery toward clinically relevant candidates.

▦ Linked Companies